Rhenman & Partners Asset Management Ab Iveric Bio, Inc. Transaction History

Rhenman & Partners Asset Management Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$18.67 - $24.56 $2.8 Million - $3.68 Million	-150,000 Reduced 34.88%	280,000 $6.81 Million
Q4 2022 Feb 13, 2023	BUY	$17.24 - $23.95 $1.12 Million - $1.56 Million	65,000 Added 17.81%	430,000 $9.21 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.08 Million - $2.14 Million	115,000 Added 46.0%	365,000 $8.73 Million
Q2 2022 Aug 12, 2022	SELL	$9.12 - $18.9 $91,199 - $189,000	-10,000 Reduced 3.85%	250,000 $2.41 Million
Q1 2022 May 13, 2022	SELL	$12.15 - $16.83 $1.09 Million - $1.51 Million	-90,000 Reduced 25.71%	260,000 $4.38 Million

Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $2.47 Million - $6.13 Million	350,000 New	350,000 $5.68 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.